All In Biotech

Drug Trial Radar · NCT00404248

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma

Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Jan 2007

Primary completion

Jun 2009

Study completion Feb 2012

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of EM-1421 and to see how well it works in treating patients with recurrent high-grade glioma.

Conditions

  • Brain and Central Nervous System Tumors

Interventions

  • terameprocolDrug

    terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.

  • pharmacological studyOther

    All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (Phase I)Time frame: first 30 days of treatment
  2. Maximum Tolerated Dose (Phase I) - Dose Limiting Toxicity (DLT)Time frame: First 30 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

    Tampa, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Josephine Ford Cancer Center at Henry Ford Hospital

    Detroit, Michigan

  • Wake Forest University Comprehensive Cancer Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.